簡要描述:
Anti-CA125 (Ovarian cancer antigen)卵巢癌抗原抗體50ug/100ug
更新時(shí)間:2024-08-17;廠商性質(zhì):經(jīng)銷商;覽量:502
卵巢癌抗原抗體 Anti-CA125 (Ovarian cancer antigen)
anti-MGr1-Ag/37LRP(P37-kDa laminin receptor precursor)(CT) 層粘連蛋白受體1抗體(C端) 50ug/100ug
Anti-MICA(MHC class I polypeptide-related sequence A) 一種細(xì)胞應(yīng)激分子抗體 50ug/100ug
Anti-Midnolin isoform Protein 1 中腦核仁蛋白1抗體 50ug/100ug
Anti-Midnolin isoform Protein 2 中腦核仁蛋白2抗體 50ug/100ug
Anti-MIF (Macrophage Migration Inhibitory Factor) 巨噬細(xì)胞移動(dòng)抑制因子抗體 50ug/100ug
Anti-MIP-1α (macrophage inflammatory protein 1α) 巨噬細(xì)胞炎癥因子1α抗體 50ug/100ug
Anti-MIP-1β (macrophage inflammatory protein 1β) 巨噬細(xì)胞炎癥因子1β 抗體 50ug/100ug
Anti-MMP-1(matrix metalloproteinases-1) 基質(zhì)金屬蛋白酶-1抗體 50ug/100ug
Anti-MMP-1(matrix metalloproteinases-1)anti-Mouse 基質(zhì)金屬蛋白酶-1抗體(小鼠) 50ug/100ug
Anti-MMP-13 (Matrix metalloproteinase 13) 基質(zhì)金屬蛋白酶13抗體 50ug/100ug
卵巢癌抗原抗體 Anti-CA125 (Ovarian cancer antigen)
Anti-MMP-14(Matrix metalloproteinase-14) 基質(zhì)金屬蛋白酶-14抗體 50ug/100ug
Anti-MMP-2(Collagenase IV /Gelatinase A/Metallo proteinase-2) 基質(zhì)金屬蛋白酶-2抗體 50ug/100ug
Anti-MMP-3(matrix metalloproteinase-3/Transin-1/SL-1/Stromelysin-1 precursor) 基質(zhì)金屬蛋白酶-3抗體 50ug/100ug
Anti-MMP-7(Matrilysin/matrix metalloproteinases-7) 基質(zhì)金屬蛋白酶-7抗體 50ug/100ug
Anti-MMP-9(matrix metalloproteinase 9) 基質(zhì)金屬蛋白酶-9抗體 50ug/100ug
Anti-β-2-MG 鼠抗人β2微球蛋白抗體(單抗) 50ug/100ug
Anti-Mo anti-KLH 小鼠抗血藍(lán)蛋白抗體 50ug/100ug
Anti-MOG (myelin oligo-dendrocyte glycoprotein-MOG) 髓鞘少樹突膠質(zhì)細(xì)胞糖蛋白抗體 50ug/100ug
Anti-Mouse anti-human HAS 鼠抗人血清白蛋白單克隆抗體 50ug/100ug
Anti-Mouse IgA 兔抗小鼠IgA抗體 50ug/100ug
Anti-CA125 (Ovarian cancer antigen)
間接染色法如果檢查未知抗原,先用已知未標(biāo)記的特異抗體(*抗體)與抗原標(biāo)本進(jìn)行反應(yīng),作用一定時(shí)間后,洗去未反應(yīng)的抗體,再用標(biāo)記的抗抗體即抗球蛋白抗體(第二抗體)與抗原標(biāo)本反應(yīng),如果*步中的抗原抗體互相發(fā)生了反應(yīng),則抗體被固定或與熒光素標(biāo)記的抗抗體結(jié)合,形成抗原-抗體-抗抗體復(fù)合物,再洗去未反應(yīng)的標(biāo)記抗抗體,在熒光顯微鏡下可見熒光。在間接染色法中,*步使用的未用熒光素標(biāo)記的抗體起著雙重作用,對(duì)抗原來說起抗體的作用,對(duì)第二步的抗抗體又起抗原作用。如果檢查未知抗體則抗原標(biāo)本為已知的待檢血清為*抗體,基他步驟和檢查抗原相同。
Anti-CA125 (Ovarian cancer antigen)